Transplant center directory

Dana-Farber Brigham Cancer Center hematopoietic stem cell transplantation program is an adult oncology effort of Dana-Farber and the Brigham and Women's Hospital. Dana-Farber Cancer Institute and Boston Children's Hospital work together to provide pediatric stem cell transplantation.

This center has been performing allogeneic transplants since 1984 and has been an NMDP/Be The Match transplant center since March 1989.

Dana-Farber Brigham Cancer Center

This center's actual 1-year survival results are above the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 759 patients.

The actual 1-year survival of these patients is 79.3%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 71.2% and 77.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 171 patients.

The actual 1-year survival of these patients is 88.7%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 78.6% and 89.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.